Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia
Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to...
Saved in:
Published in | Frontiers in immunology Vol. 12; p. 730970 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers
17.12.2021
Frontiers Media S.A |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation
as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation
, suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML. |
---|---|
AbstractList | Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation in vitro as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation in vitro, suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML. Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation in vitro as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation in vitro , suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML. Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to reduced anti-tumor potential. Our limited understanding of the mechanisms underlying these defects hampers the development of strategies to restore NK cell potential. Here, we have used a mouse model of AML to gain insight into these mechanisms. We found that leukemia progression resulted in NK cell maturation defects and functional alterations. Next, we assessed NK cell cytokine signaling governing their behavior. We showed that NK cells from leukemic mice exhibit constitutive IL-15/mTOR signaling and type I IFN signaling. However, these cells failed to respond to IL-15 stimulation as illustrated by reduced activation of the mTOR pathway. Moreover, our data suggest that mTOR-mediated metabolic responses were reduced in NK cells from AML-bearing mice. Noteworthy, the reduction of mTOR-mediated activation of NK cells during AML development partially rescued NK cell metabolic and functional defects. Altogether, our data strongly suggest that NK cells from leukemic mice are metabolically and functionally exhausted as a result of a chronic cytokine activation, at least partially IL-15/mTOR signaling. NK cells from AML patients also displayed reduced IL-2/15Rβ expression and showed cues of reduced metabolic response to IL-15 stimulation , suggesting that a similar mechanism might occur in AML patients. Our study pinpoints the dysregulation of cytokine stimulation pathways as a new mechanism leading to NK cell defects in AML. |
Author | Fares, Joanna Bou-Tayeh, Berna Aurrand-Lions, Michel Leblanc, Raphael Bidaut, Ghislain Walzer, Thierry Balzano, Marielle Just-Landi, Sylvaine Salem, Nassim Laletin, Vladimir Kerdiles, Yann M Olive, Daniel Fauriat, Cyril Nunès, Jacques A Hérault, Olivier |
AuthorAffiliation | 5 Centre National de la Recherche Scientifique (CNRS) UMR 7292, LNOx Team, François Rabelais University , Tours , France 4 Cibi Technological Platform, Cancer Research Center of Marseille (CRCM) , Marseille , France 2 IBiSA Immunomonitoring Platform, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM) , Marseille , France 3 Aix-Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie de Marseille-Luminy (CIML) , Marseille , France 6 Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308 , Lyon , France 1 Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM) , Marseille , France |
AuthorAffiliation_xml | – name: 1 Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM) , Marseille , France – name: 6 Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308 , Lyon , France – name: 4 Cibi Technological Platform, Cancer Research Center of Marseille (CRCM) , Marseille , France – name: 3 Aix-Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie de Marseille-Luminy (CIML) , Marseille , France – name: 5 Centre National de la Recherche Scientifique (CNRS) UMR 7292, LNOx Team, François Rabelais University , Tours , France – name: 2 IBiSA Immunomonitoring Platform, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM) , Marseille , France |
Author_xml | – sequence: 1 givenname: Berna surname: Bou-Tayeh fullname: Bou-Tayeh, Berna organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 2 givenname: Vladimir surname: Laletin fullname: Laletin, Vladimir organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 3 givenname: Nassim surname: Salem fullname: Salem, Nassim organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 4 givenname: Sylvaine surname: Just-Landi fullname: Just-Landi, Sylvaine organization: IBiSA Immunomonitoring Platform, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 5 givenname: Joanna surname: Fares fullname: Fares, Joanna organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 6 givenname: Raphael surname: Leblanc fullname: Leblanc, Raphael organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 7 givenname: Marielle surname: Balzano fullname: Balzano, Marielle organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 8 givenname: Yann M surname: Kerdiles fullname: Kerdiles, Yann M organization: Aix-Marseille Université, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie de Marseille-Luminy (CIML), Marseille, France – sequence: 9 givenname: Ghislain surname: Bidaut fullname: Bidaut, Ghislain organization: Cibi Technological Platform, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 10 givenname: Olivier surname: Hérault fullname: Hérault, Olivier organization: Centre National de la Recherche Scientifique (CNRS) UMR 7292, LNOx Team, François Rabelais University, Tours, France – sequence: 11 givenname: Daniel surname: Olive fullname: Olive, Daniel organization: IBiSA Immunomonitoring Platform, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 12 givenname: Michel surname: Aurrand-Lions fullname: Aurrand-Lions, Michel organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 13 givenname: Thierry surname: Walzer fullname: Walzer, Thierry organization: Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, Ecole Normale Supérieure de Lyon, Université Lyon 1, CNRS UMR5308, Lyon, France – sequence: 14 givenname: Jacques A surname: Nunès fullname: Nunès, Jacques A organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France – sequence: 15 givenname: Cyril surname: Fauriat fullname: Fauriat, Cyril organization: Aix-Marseille Université UM105, Centre National de la Recherche Scientifique (CNRS) UMR7258, Inserm UMR1068, Institut Paoli-Calmettes, Cancer Research Center of Marseille (CRCM), Marseille, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34975835$$D View this record in MEDLINE/PubMed https://amu.hal.science/hal-03566016$$DView record in HAL |
BookMark | eNpdkktvEzEUhUeoiJbSH8AGeQmLBL8fG6QoPBqRUomWtWV77MTFM049M5XKr2eSKVWLN7bvPeezrnVeV0dtbn1VvUVwTohUH0NsmmGOIUZzQaAS8EV1gjinM4IxPXpyPq7Ouu4GjosqQgh7VR0TqgSThJ1Uf5bbktvowGo9Qwxc9bEZkuljboFpa7BqdiYWX4Pm-vInuIqb1qTYbg69C98bm1PsGhBb8MP0QzEJfI8p-QKWPqUOfB7KXr1wQ-_Bxb1POdZg7YffvonmTfUymNT5s4f9tPr19cv18ny2vvy2Wi7WM0eV6mdOmJoGIZWnwhsCsQ8yBCQJ4dAwgpGsmVWS4kCDcqhGkEnKrXOKSmEDI6fVauLW2dzoXYmNKfc6m6gPhVw22pQ-uuQ1FVwFz6VlCFFcW2vHKxHCO0stYmZkfZpYu8E2vna-7cehn0Gfd9q41Zt8p6VAkgs1Aj5MgO1_tvPFWu9rkDDOIeJ3aNS-f3is5NvBd71uYufGjzWtz0OnMUccSyQlHqVokrqSu6748MhGUO_jog9x0fu46Ckuo-fd01keHf_CQf4C8T--DA |
CitedBy_id | crossref_primary_10_3389_fimmu_2023_1141208 crossref_primary_10_1080_2162402X_2023_2175517 crossref_primary_10_1186_s12964_023_01428_2 crossref_primary_10_3390_jpm12122025 crossref_primary_10_3390_cancers15030705 crossref_primary_10_1016_j_intimp_2024_112156 crossref_primary_10_1080_10428194_2023_2218508 crossref_primary_10_1007_s12185_024_03732_0 |
Cites_doi | 10.1016/S0140-6736(18)31041-9 10.3390/cancers9100132 10.1172/JCI125916 10.1016/j.coi.2016.01.007 10.3389/fimmu.2013.00450 10.1182/blood.V100.2.560 10.1101/648501 10.3389/fimmu.2017.00064 10.1038/icb.2014.1 10.1172/JCI85413 10.1080/10245332.2018.1486064 10.3791/54270 10.1038/s41423-020-00574-8 10.1038/sj.leu.2401578 10.1016/j.ccr.2007.08.020 10.4161/15384101.2014.972919 10.1182/blood-2018-03-838474 10.1371/JOURNAL.PONE.0201170 10.1182/blood-2016-02-698027 10.1038/s41577-019-0139-2 10.1084/jem.20071913 10.3389/FIMMU.2021.695051 10.1038/ni.3809 10.1182/blood-2008-10-187179 10.1158/1078-0432.CCR-12-3603 10.4049/jimmunol.167.3.1179 10.1007/S12185-021-03209-4 10.1073/pnas.0307442101 10.1038/s41590-018-0132-0 10.4049/jimmunol.1800086 10.1016/j.cyto.2012.12.023 10.1002/eji.201747299 10.1016/j.celrep.2020.107720 10.1126/scisignal.aad1884 10.1038/ni.2936 10.1038/ni.3800 10.1016/j.cell.2018.07.017 10.1016/j.immuni.2007.03.006 10.4049/JIMMUNOL.2100023 10.1016/j.stem.2020.05.008 10.1182/blood-2005-08-027979 10.1016/j.coi.2016.10.004 10.1182/blood-2012-03-415364 10.3389/fimmu.2014.00160 10.1016/j.cyto.2018.03.033 10.1038/ni.3470 10.1046/j.1365-2141.2002.03803.x 10.1016/j.ccell.2016.05.011 10.1073/pnas.2020459118 10.1016/j.humimm.2013.11.014 10.3389/fimmu.2017.00573 10.1080/10428194.2018.1546854 10.3389/fimmu.2017.00931 10.1038/s41577-018-0061-z 10.1684/ecn.2010.0207 10.1073/pnas.1112064108 10.1038/nri3044 10.1172/jci.insight.96219 10.1038/s42003-020-1027-9 10.3324/haematol.2013.087536 10.1016/j.it.2018.04.009 10.3389/fimmu.2016.00094 10.1182/blood-2017-12-823757 10.1016/j.coi.2018.11.003 10.1016/J.CMET.2020.11.007 10.1038/s41467-021-25758-2 10.1172/jci.insight.127729 10.3390/ijms20184514 10.4049/jimmunol.1401558 10.18632/oncotarget.17747 10.1080/2162402X.2017.1307491 10.1073/pnas.1012128107 10.1016/S1074-7613(02)00429-6 10.1016/j.celrep.2021.109210 10.1038/ncomms12730 10.1182/bloodadvances.2019001124 10.1182/blood-2007-09-077438 10.4049/jimmunol.1701461 10.1038/ni1582 10.1182/blood-2010-07-293332 10.1056/NEJMra1406184 10.3389/fimmu.2014.00187 10.1093/nar/gkw377 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat. Attribution Copyright © 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat |
Copyright_xml | – notice: Copyright © 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat. – notice: Attribution – notice: Copyright © 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 1XC VOOES 5PM DOA |
DOI | 10.3389/fimmu.2021.730970 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
EndPage | 730970 |
ExternalDocumentID | oai_doaj_org_article_4769fe68b51142dbbb9fe377ecb4b15a oai_HAL_hal_03566016v1 10_3389_fimmu_2021_730970 34975835 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CGR CUY CVF DIK EBS ECM EIF EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM OK1 PGMZT RIG RNS RPM AAYXX CITATION 7X8 1XC VOOES 5PM |
ID | FETCH-LOGICAL-c499t-c7ad4f789e47ea302ef8ff183360a53218d5b9842f4f9c1d105846bcc9487bf53 |
IEDL.DBID | RPM |
ISSN | 1664-3224 |
IngestDate | Tue Oct 22 15:08:56 EDT 2024 Tue Sep 17 21:17:46 EDT 2024 Wed Nov 13 07:09:28 EST 2024 Sat Oct 26 01:40:04 EDT 2024 Thu Nov 21 22:45:33 EST 2024 Sat Sep 28 08:22:29 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | exhaustion natural killer cells IL-15/mTOR signaling metabolism acute myeloid leukemia chronic stimulation |
Language | English |
License | Copyright © 2021 Bou-Tayeh, Laletin, Salem, Just-Landi, Fares, Leblanc, Balzano, Kerdiles, Bidaut, Hérault, Olive, Aurrand-Lions, Walzer, Nunès and Fauriat. Attribution: http://creativecommons.org/licenses/by This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c499t-c7ad4f789e47ea302ef8ff183360a53218d5b9842f4f9c1d105846bcc9487bf53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC8718679 Edited by: Salvatore Valitutti, Institut National de la Santé et de la Recherche Médicale (INSERM), France Reviewed by: Alvaro Teijeira, University of Navarra, Spain; Laura Patrussi, University of Siena, Italy Present address: Joanna Fares, Innate Pharma S.A., Marseille, France; Marielle Balzano, BioCytex, Marseille, France This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology |
ORCID | 0000-0003-1299-4113 0000-0002-8361-3034 0000-0002-4850-6831 0000-0002-0857-8179 0000-0003-4865-0400 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718679/ |
PMID | 34975835 |
PQID | 2616281882 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_4769fe68b51142dbbb9fe377ecb4b15a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8718679 hal_primary_oai_HAL_hal_03566016v1 proquest_miscellaneous_2616281882 crossref_primary_10_3389_fimmu_2021_730970 pubmed_primary_34975835 |
PublicationCentury | 2000 |
PublicationDate | 2021-12-17 |
PublicationDateYYYYMMDD | 2021-12-17 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-17 day: 17 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in immunology |
PublicationTitleAlternate | Front Immunol |
PublicationYear | 2021 |
Publisher | Frontiers Frontiers Media S.A |
Publisher_xml | – name: Frontiers – name: Frontiers Media S.A |
References | Frutoso (B55) 2018; 201 Mundy-Bosse (B37) 2016; 126 Levéen (B44) 2002; 100 Donnelly (B60) 2014; 193 Biederstädt (B84) 2021; 1 Stavropoulou (B46) 2016; 30 Zhu (B75) 2020 Yang (B79) 2016; 7 Merino (B81) 2019; 129 Gao (B70) 2017; 18 Fauriat (B74) 2007; 109 Mortier (B18) 2008; 205 Vivier (B6) 2018; 174 Chretien (B31) 2017; 8 Sun (B39) 2014; 75 Zhang (B53) 2021; 12 Mao (B25) 2016; 128 Short (B4) 2018; 392 Sun (B13) 2011; 11 Argüello (B78) 2020; 32 Imamura (B49) 2002; 119 Dulphy (B36) 2016; 7 Stringaris (B30) 2014; 99 Mopin (B50) 2016; 2016 Keating (B23) 2019; 118 Nandagopal (B26) 2014; 5 Chretien (B32) 2017; 6 Limongello (B3) 2021; 12 Schluns (B20) 2004; 101 Perdreau (B56) 2010; 21 Bergmann (B72) 1995; 23 Ahl (B77) 2020; 3 Chretien (B33) 2021; 118 Marçais (B54) 2014; 13 Bewersdorf (B2) 2019; 60 Felices (B57) 2018; 3 Zaiatz-Bittencourt (B62) 2018; 200 Marçais (B14) 2013; 4 Scoville (B69) 2018; 132 Sanchez-Correa (B41) 2013; 61 Sanchez-Correa (B82) 2017; 8 Romee (B83) 2018; 131 Wilhelm (B45) 2011; 117 Lawrence (B48) 1999; 13 Rautela (B16) 2017; 44 Crinier (B34) 2021; 18 Zhang (B66) 2018; 19 Viel (B64) 2017; 9 Chiossone (B10) 2009; 113 Marçais (B15) 2014; 15 Guasch (B43) 2007; 12 Frutoso (B80) 2019; 20 Çelik (B40) 2020; 4 Vivier (B11) 2008; 9 Gill (B65) 2012; 119 Zhang (B51) 2018; 48 Hong (B73) 2014; 5 Wagner (B52) 2020; 31 Mishra (B22) 2014; 20 Rey (B67) 2017; 8 Sheppard (B27) 2021; 35 O’Brien (B28) 2019; 19 Viel (B61) 2016; 9 Cortez (B71) 2017; 18 Elpek (B58) 2010; 107 Salzberger (B68) 2018; 13 Locatelli (B5) 2018; 39 Narni-Mancinelli (B42) 2011; 108 Chiossone (B12) 2018; 18 Kuleshov (B47) 2016; 44 Mattei (B76) 2001; 167 Lordo (B35) 2021; 207 Alvarez (B59) 2019; 4 Slattery (B63) 2019; 648501 Döhner (B1) 2015; 373 Caligiuri (B7) 2008; 112 Geiger (B9) 2016; 39 Huntington (B21) 2014; 92 Delconte (B24) 2016; 17 Lucas (B19) 2007; 26 Chretien (B29) 2017; 8 Wang (B38) 2018; 23 Dubois (B17) 2002; 17 Scoville (B8) 2019; 56 |
References_xml | – volume: 392 start-page: 593 year: 2018 ident: B4 article-title: Acute Myeloid Leukaemia publication-title: Lancet doi: 10.1016/S0140-6736(18)31041-9 contributor: fullname: Short – volume: 9 year: 2017 ident: B64 article-title: Regulation of mTOR Metabolic Fitness and Effector Functions by Cytokines in Natural Killer Cells publication-title: Cancers (Basel) doi: 10.3390/cancers9100132 contributor: fullname: Viel – volume: 129 year: 2019 ident: B81 article-title: Chronic Stimulation Drives Human NK Cell Dysfunction and Epigenetic Reprograming publication-title: J Clin Invest doi: 10.1172/JCI125916 contributor: fullname: Merino – volume: 39 year: 2016 ident: B9 article-title: Development and Maturation of Natural Killer Cells publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2016.01.007 contributor: fullname: Geiger – volume: 4 year: 2013 ident: B14 article-title: Regulation of Mouse NK Cell Development and Function by Cytokines publication-title: Front Immunol doi: 10.3389/fimmu.2013.00450 contributor: fullname: Marçais – volume: 100 year: 2002 ident: B44 article-title: Induced Disruption of the Transforming Growth Factor Beta Type II Receptor Gene in Mice Causes a Lethal Inflammatory Disorder That is Transplantable publication-title: Blood doi: 10.1182/blood.V100.2.560 contributor: fullname: Levéen – volume: 648501 year: 2019 ident: B63 article-title: Tgfβ Drives Mitochondrial Dysfunction in Peripheral Blood NK Cells During Metastatic Breast Cancer publication-title: bioRxiv doi: 10.1101/648501 contributor: fullname: Slattery – volume: 8 year: 2017 ident: B67 article-title: Kinetics of Cytotoxic Lymphocytes Reconstitution After Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells publication-title: Front Immunol doi: 10.3389/fimmu.2017.00064 contributor: fullname: Rey – volume: 92 year: 2014 ident: B21 article-title: The Unconventional Expression of IL-15 and its Role in NK Cell Homeostasis publication-title: Immunol Cell Biol doi: 10.1038/icb.2014.1 contributor: fullname: Huntington – volume: 126 year: 2016 ident: B37 article-title: MicroRNA-29b Mediates Altered Innate Immune Development in Acute Leukemia publication-title: J Clin Invest doi: 10.1172/JCI85413 contributor: fullname: Mundy-Bosse – volume: 23 year: 2018 ident: B38 article-title: Roles of the Bone Marrow Niche in Hematopoiesis, Leukemogenesis, and Chemotherapy Resistance in Acute Myeloid Leukemia publication-title: Hematology doi: 10.1080/10245332.2018.1486064 contributor: fullname: Wang – volume: 2016 year: 2016 ident: B50 article-title: A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model publication-title: J Vis Exp doi: 10.3791/54270 contributor: fullname: Mopin – volume: 18 year: 2021 ident: B34 article-title: Single-Cell Profiling Reveals the Trajectories of Natural Killer Cell Differentiation in Bone Marrow and a Stress Signature Induced by Acute Myeloid Leukemia publication-title: Cell Mol Immunol doi: 10.1038/s41423-020-00574-8 contributor: fullname: Crinier – volume: 13 year: 1999 ident: B48 article-title: Frequent Co-Expression of the HOXA9 and MEIS1 Homeobox Genes in Human Myeloid Leukemias publication-title: Leukemia doi: 10.1038/sj.leu.2401578 contributor: fullname: Lawrence – volume: 12 year: 2007 ident: B43 article-title: Loss of Tgfβ Signaling Destabilizes Homeostasis and Promotes Squamous Cell Carcinomas in Stratified Epithelia publication-title: Cancer Cell doi: 10.1016/j.ccr.2007.08.020 contributor: fullname: Guasch – volume: 13 year: 2014 ident: B54 article-title: MTOR: A Gate to NK Cell Maturation and Activation publication-title: Cell Cycle doi: 10.4161/15384101.2014.972919 contributor: fullname: Marçais – volume: 132 year: 2018 ident: B69 article-title: Human AML Activates the Aryl Hydrocarbon Receptor Pathway to Impair NK Cell Development and Function publication-title: Blood doi: 10.1182/blood-2018-03-838474 contributor: fullname: Scoville – volume: 13 year: 2018 ident: B68 article-title: Tissue-Resident NK Cells Differ in Their Expression Profile of the Nutrient Transporters Glut1, CD98 and CD71 publication-title: PloS One doi: 10.1371/JOURNAL.PONE.0201170 contributor: fullname: Salzberger – volume: 128 year: 2016 ident: B25 article-title: IL-15 Activates mTOR and Primes Stress-Activated Gene Expression Leading to Prolonged Antitumor Capacity of NK Cells publication-title: Blood doi: 10.1182/blood-2016-02-698027 contributor: fullname: Mao – volume: 19 year: 2019 ident: B28 article-title: Immunometabolism and Natural Killer Cell Responses publication-title: Nat Rev Immunol doi: 10.1038/s41577-019-0139-2 contributor: fullname: O’Brien – volume: 205 year: 2008 ident: B18 article-title: IL-15rα Chaperones IL-15 to Stable Dendritic Cell Membrane Complexes That Activate NK Cells publication-title: Via Trans Presentation J Exp Med doi: 10.1084/jem.20071913 contributor: fullname: Mortier – volume: 12 year: 2021 ident: B3 article-title: Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia publication-title: Front Immunol doi: 10.3389/FIMMU.2021.695051 contributor: fullname: Limongello – volume: 18 start-page: 995 year: 2017 ident: B71 article-title: SMAD4 Impedes the Conversion of NK Cells Into ILC1-Like Cells by Curtailing non-Canonical TGF-β Signaling publication-title: Nat Immunol doi: 10.1038/ni.3809 contributor: fullname: Cortez – volume: 113 year: 2009 ident: B10 article-title: Maturation of Mouse NK Cells is a 4-Stage Developmental Program publication-title: Blood doi: 10.1182/blood-2008-10-187179 contributor: fullname: Chiossone – volume: 20 year: 2014 ident: B22 article-title: Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-3603 contributor: fullname: Mishra – volume: 167 year: 2001 ident: B76 article-title: IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation publication-title: J Immunol doi: 10.4049/jimmunol.167.3.1179 contributor: fullname: Mattei – volume: 1 start-page: 1 year: 2021 ident: B84 article-title: Engineering the Next Generation of CAR-NK Immunotherapies publication-title: Int J Hematol doi: 10.1007/S12185-021-03209-4 contributor: fullname: Biederstädt – volume: 101 year: 2004 ident: B20 article-title: Distinct Cell Types Control Lymphoid Subset Development by Means of IL-15 and IL-15 Receptor α Expression publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0307442101 contributor: fullname: Schluns – volume: 19 year: 2018 ident: B66 article-title: Blockade of the Checkpoint Receptor TIGIT Prevents NK Cell Exhaustion and Elicits Potent Anti-Tumor Immunity publication-title: Nat Immunol doi: 10.1038/s41590-018-0132-0 contributor: fullname: Zhang – volume: 23 year: 1995 ident: B72 article-title: The Inhibition of Lymphokine-Activated Killer Cells in Acute Myeloblastic Leukemia is Mediated by Transforming Growth Factor-Beta 1 publication-title: Exp Hematol contributor: fullname: Bergmann – volume: 201 start-page: 493 year: 2018 ident: B55 article-title: Emergence of NK Cell Hyporesponsiveness After Two IL-15 Stimulation Cycles publication-title: J Immunol doi: 10.4049/jimmunol.1800086 contributor: fullname: Frutoso – volume: 61 year: 2013 ident: B41 article-title: Cytokine Profiles in Acute Myeloid Leukemia Patients at Diagnosis: Survival is Inversely Correlated With IL-6 and Directly Correlated With IL-10 Levels publication-title: Cytokine doi: 10.1016/j.cyto.2012.12.023 contributor: fullname: Sanchez-Correa – volume: 48 year: 2018 ident: B51 article-title: T-Bet and Eomes Govern Differentiation and Function of Mouse and Human NK Cells and ILC1 publication-title: Eur J Immunol doi: 10.1002/eji.201747299 contributor: fullname: Zhang – volume: 31 year: 2020 ident: B52 article-title: Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity publication-title: Cell Rep doi: 10.1016/j.celrep.2020.107720 contributor: fullname: Wagner – volume: 9 year: 2016 ident: B61 article-title: TGF-β Inhibits the Activation and Functions of NK Cells by Repressing the mTOR Pathway publication-title: Sci Signal doi: 10.1126/scisignal.aad1884 contributor: fullname: Viel – volume: 15 year: 2014 ident: B15 article-title: The Metabolic Checkpoint Kinase mTOR is Essential for IL-15 Signaling During the Development and Activation of NK Cells publication-title: Nat Immunol doi: 10.1038/ni.2936 contributor: fullname: Marçais – volume: 18 year: 2017 ident: B70 article-title: Tumor Immunoevasion by the Conversion of Effector NK Cells Into Type 1 Innate Lymphoid Cells publication-title: Nat Immunol doi: 10.1038/ni.3800 contributor: fullname: Gao – volume: 174 year: 2018 ident: B6 article-title: Innate Lymphoid Cells: 10 Years on publication-title: Cell doi: 10.1016/j.cell.2018.07.017 contributor: fullname: Vivier – volume: 26 year: 2007 ident: B19 article-title: Dendritic Cells Prime Natural Killer Cells by Trans-Presenting Interleukin 15 publication-title: Immunity doi: 10.1016/j.immuni.2007.03.006 contributor: fullname: Lucas – volume: 207 year: 2021 ident: B35 article-title: Acute Myeloid Leukemia Alters Group 1 Innate Lymphoid Cell Differentiation From a Common Precursor publication-title: J Immunol doi: 10.4049/JIMMUNOL.2100023 contributor: fullname: Lordo – year: 2020 ident: B75 article-title: Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-Tumor Activity publication-title: Cell Stem Cell doi: 10.1016/j.stem.2020.05.008 contributor: fullname: Zhu – volume: 109 year: 2007 ident: B74 article-title: Deficient Expression of NCR in NK Cells From Acute Myeloid Leukemia: Evolution During Leukemia Treatment and Impact of Leukemia Cells in NCRdull Phenotype Induction publication-title: Blood doi: 10.1182/blood-2005-08-027979 contributor: fullname: Fauriat – volume: 44 start-page: 1 year: 2017 ident: B16 article-title: IL-15 Signaling in NK Cell Cancer Immunotherapy publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2016.10.004 contributor: fullname: Rautela – volume: 119 year: 2012 ident: B65 article-title: Rapid Development of Exhaustion and Down-Regulation of Eomesodermin Limit the Antitumor Activity of Adoptively Transferred Murine Natural Killer Cells publication-title: Blood doi: 10.1182/blood-2012-03-415364 contributor: fullname: Gill – volume: 5 year: 2014 ident: B73 article-title: Plasma Exosomes as Markers of Therapeutic Response in Patients With Acute Myeloid Leukemia publication-title: Front Immunol doi: 10.3389/fimmu.2014.00160 contributor: fullname: Hong – volume: 118 start-page: 64 year: 2019 ident: B23 article-title: SOCS-Mediated Immunomodulation of Natural Killer Cells publication-title: Cytokine doi: 10.1016/j.cyto.2018.03.033 contributor: fullname: Keating – volume: 17 year: 2016 ident: B24 article-title: CIS Is a Potent Checkpoint in NK Cell-Mediated Tumor Immunity publication-title: Nat Immunol doi: 10.1038/ni.3470 contributor: fullname: Delconte – volume: 119 year: 2002 ident: B49 article-title: Frequent Co-Expression of HoxA9 and Meis1 Genes in Infant Acute Lymphoblastic Leukaemia With MLL Rearrangement publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2002.03803.x contributor: fullname: Imamura – volume: 30 start-page: 43 year: 2016 ident: B46 article-title: MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.05.011 contributor: fullname: Stavropoulou – volume: 118 year: 2021 ident: B33 article-title: High-Dimensional Mass Cytometry Analysis of NK Cell Alterations in AML Identifies a Subgroup With Adverse Clinical Outcome publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.2020459118 contributor: fullname: Chretien – volume: 75 year: 2014 ident: B39 article-title: The Imbalanced Profile and Clinical Significance of T Helper Associated Cytokines in Bone Marrow Microenvironment of the Patients With Acute Myeloid Leukemia publication-title: Hum Immunol doi: 10.1016/j.humimm.2013.11.014 contributor: fullname: Sun – volume: 8 year: 2017 ident: B29 article-title: Natural Killer Defective Maturation is Associated With Adverse Clinical Outcome in Patients With Acute Myeloid Leukemia publication-title: Front Immunol doi: 10.3389/fimmu.2017.00573 contributor: fullname: Chretien – volume: 60 year: 2019 ident: B2 article-title: Are We Witnessing the Start of a Therapeutic Revolution in Acute Myeloid Leukemia publication-title: Leuk Lymphoma doi: 10.1080/10428194.2018.1546854 contributor: fullname: Bewersdorf – volume: 8 year: 2017 ident: B82 article-title: In Vitro Culture With Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients publication-title: Front Immunol doi: 10.3389/fimmu.2017.00931 contributor: fullname: Sanchez-Correa – volume: 18 year: 2018 ident: B12 article-title: Natural Killer Cells and Other Innate Lymphoid Cells in Cancer publication-title: Nat Rev Immunol doi: 10.1038/s41577-018-0061-z contributor: fullname: Chiossone – volume: 21 start-page: 297 year: 2010 ident: B56 article-title: Different Dynamics of IL-15R Activation Following IL-15 Cis- or Trans-Presentation publication-title: Eur Cytokine Netw doi: 10.1684/ecn.2010.0207 contributor: fullname: Perdreau – volume: 108 year: 2011 ident: B42 article-title: Fate Mapping Analysis of Lymphoid Cells Expressing the NKp46 Cell Surface Receptor publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1112064108 contributor: fullname: Narni-Mancinelli – volume: 11 year: 2011 ident: B13 article-title: NK Cell Development, Homeostasis and Function: Parallels With CD8 + T Cells publication-title: Nat Rev Immunol doi: 10.1038/nri3044 contributor: fullname: Sun – volume: 3 start-page: 1 year: 2018 ident: B57 article-title: Continuous Treatment With IL-15 Exhausts Human NK Cells publication-title: Via Metab Defect JCI Insight doi: 10.1172/jci.insight.96219 contributor: fullname: Felices – volume: 3 start-page: 1 year: 2020 ident: B77 article-title: Met-Flow, a Strategy for Single-Cell Metabolic Analysis Highlights Dynamic Changes in Immune Subpopulations publication-title: Commun Biol 2020 31 doi: 10.1038/s42003-020-1027-9 contributor: fullname: Ahl – volume: 99 year: 2014 ident: B30 article-title: Leukemia-Induced Phenotypic and Functional Defects in Natural Killer Cells Predict Failure to Achieve Remission in Acute Myeloid Leukemia publication-title: Haematologica doi: 10.3324/haematol.2013.087536 contributor: fullname: Stringaris – volume: 39 year: 2018 ident: B5 article-title: NK Cells Mediate a Crucial Graft-Versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia publication-title: Trends Immunol doi: 10.1016/j.it.2018.04.009 contributor: fullname: Locatelli – volume: 7 year: 2016 ident: B36 article-title: Underground Adaptation to a Hostile Environment : Acute Myeloid Leukemia vs. Natural Killer Cells publication-title: Front Immunol doi: 10.3389/fimmu.2016.00094 contributor: fullname: Dulphy – volume: 131 year: 2018 ident: B83 article-title: First-In-Human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse After Transplantation publication-title: Blood doi: 10.1182/blood-2017-12-823757 contributor: fullname: Romee – volume: 56 year: 2019 ident: B8 article-title: Cellular Pathways in the Development of Human and Murine Innate Lymphoid Cells publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2018.11.003 contributor: fullname: Scoville – volume: 32 start-page: 1063 year: 2020 ident: B78 article-title: SCENITH: A Flow Cytometry Based Method to Functionally Profile Energy Metabolism With Single Cell Resolution publication-title: Cell Metab doi: 10.1016/J.CMET.2020.11.007 contributor: fullname: Argüello – volume: 12 start-page: 1 year: 2021 ident: B53 article-title: Sequential Actions of EOMES and T-BET Promote Stepwise Maturation of Natural Killer Cells publication-title: Nat Commun 2021 121 doi: 10.1038/s41467-021-25758-2 contributor: fullname: Zhang – volume: 4 year: 2019 ident: B59 article-title: Regulation of Murine NK Cell Exhaustion Through the Activation of the DNA Damage Repair Pathway publication-title: JCI Insight doi: 10.1172/jci.insight.127729 contributor: fullname: Alvarez – volume: 20 year: 2019 ident: B80 article-title: NK Cell Hyporesponsiveness: More is Not Always Better publication-title: Int J Mol Sci doi: 10.3390/ijms20184514 contributor: fullname: Frutoso – volume: 193 year: 2014 ident: B60 article-title: Mtorc1-Dependent Metabolic Reprogramming Is a Prerequisite for NK Cell Effector Function publication-title: J Immunol doi: 10.4049/jimmunol.1401558 contributor: fullname: Donnelly – volume: 8 year: 2017 ident: B31 article-title: NKp30 Expression is a Prognostic Immune Biomarker for Stratification of Patients With Intermediate-Risk Acute Myeloid Leukemia publication-title: Oncotarget doi: 10.18632/oncotarget.17747 contributor: fullname: Chretien – volume: 6 year: 2017 ident: B32 article-title: NKp46 Expression on NK Cells as a Prognostic and Predictive Biomarker for Response to Allo-SCT in Patients With AML publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1307491 contributor: fullname: Chretien – volume: 107 year: 2010 ident: B58 article-title: Mature Natural Killer Cells With Phenotypic and Functional Alterations Accumulate Upon Sustained Stimulation With IL-15/IL-15rα Complexes publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1012128107 contributor: fullname: Elpek – volume: 17 year: 2002 ident: B17 article-title: IL-15rα Recycles and Presents IL-15 in Trans to Neighboring Cells publication-title: Immunity doi: 10.1016/S1074-7613(02)00429-6 contributor: fullname: Dubois – volume: 35 year: 2021 ident: B27 article-title: Lactate Dehydrogenase A-Dependent Aerobic Glycolysis Promotes Natural Killer Cell Anti-Viral and Anti-Tumor Function publication-title: Cell Rep doi: 10.1016/j.celrep.2021.109210 contributor: fullname: Sheppard – volume: 7 year: 2016 ident: B79 article-title: NK Cell Development Requires Tsc1-Dependent Negative Regulation of IL-15-Triggered Mtorc1 Activation publication-title: Nat Commun doi: 10.1038/ncomms12730 contributor: fullname: Yang – volume: 4 year: 2020 ident: B40 article-title: Highly Multiplexed Proteomic Assessment of Human Bone Marrow in Acute Myeloid Leukemia publication-title: Blood Adv doi: 10.1182/bloodadvances.2019001124 contributor: fullname: Çelik – volume: 112 year: 2008 ident: B7 article-title: Human Natural Killer Cells publication-title: Blood doi: 10.1182/blood-2007-09-077438 contributor: fullname: Caligiuri – volume: 200 year: 2018 ident: B62 article-title: Canonical TGF-β Signaling Pathway Represses Human NK Cell Metabolism publication-title: J Immunol doi: 10.4049/jimmunol.1701461 contributor: fullname: Zaiatz-Bittencourt – volume: 9 year: 2008 ident: B11 article-title: Functions of Natural Killer Cells publication-title: Nat Immunol doi: 10.1038/ni1582 contributor: fullname: Vivier – volume: 117 year: 2011 ident: B45 article-title: RNA-Seq Analysis of 2 Closely Related Leukemia Clones That Differ in Their Self-Renewal Capacity publication-title: Blood doi: 10.1182/blood-2010-07-293332 contributor: fullname: Wilhelm – volume: 373 year: 2015 ident: B1 article-title: Acute Myeloid Leukemia publication-title: N Engl J Med doi: 10.1056/NEJMra1406184 contributor: fullname: Döhner – volume: 5 year: 2014 ident: B26 article-title: The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions publication-title: Front Immunol doi: 10.3389/fimmu.2014.00187 contributor: fullname: Nandagopal – volume: 44 year: 2016 ident: B47 article-title: Enrichr: A Comprehensive Gene Set Enrichment Analysis Web Server 2016 Update publication-title: Nucleic Acids Res doi: 10.1093/nar/gkw377 contributor: fullname: Kuleshov |
SSID | ssj0000493335 |
Score | 2.4007869 |
Snippet | Natural Killer (NK) cells are potent anti-leukemic immune effectors. However, they display multiple defects in acute myeloid leukemia (AML) patients leading to... |
SourceID | doaj pubmedcentral hal proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 730970 |
SubjectTerms | acute myeloid leukemia Animals Case-Control Studies Cells, Cultured chronic stimulation Disease Models, Animal exhaustion Female Humans IL-15/mTOR signaling Immunology Interleukin-15 - metabolism Interleukin-15 - pharmacology Killer Cells, Natural - immunology Leukemia, Myeloid, Acute - blood Leukemia, Myeloid, Acute - immunology Life Sciences Male metabolism Mice Mice, Inbred C57BL Mice, Transgenic natural killer cells Signal Transduction - drug effects Signal Transduction - genetics TOR Serine-Threonine Kinases - metabolism |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwFLRQJSQuiPIZvmQQJ6TQZG3H8XEpVFvYLRJtpd4s23luA5tsxSZI5dfzHKfVLhy4cIkUJ7ITz3M8o9jzCHljuc2d5yJlLK9SnoNNlVOQMrDWGjwwGTYKL46K2Sn_dCbONlJ9hTVh0R44dtwel4XyUJRWhF2fFdaAp0xKcKEZEalRNtkQU98i72WMifgbE1WY2vN10_SoByf5OwxqFZITb0xEg18_Ti8XYTXk31TzzxWTG1PQwT1yd-SOdBqfeZfcgvY-uR2zSV49IL9Go1t6OE9zQY-7uhlzc1HTVvQQBz5-3yranHz5So_r80DB2_Ph2gI6DIZlvW5o3dIjM5hx0M_DPkG6D8vlmn4Y9jPSqes7oIsrWK7qis6h_w5NbR6S04OPJ_uzdEytkDqUOF3qpKm4l6UCLsGwbAK-9B6HNysyIxjO-5WwquQTz71yeYUsDImKdU6hwLFesEdkp1218ITQCglHBqwUmc-4ldw466Q3zguLEBQsIW-v-1lfRgcNjcojgKIHUHQARUdQEvI-IHFzYzC_HgowJPQYEvpfIZGQ14jjVh2z6VyHsowhfUWW-zNPyKtrmDWOqPCbxLSw6tcaNWURPLLKSUIeR9hv6mJcocBiIiFyKyC2Gtu-0tYXg2s3KtNgbvj0f7zhM3IndFpYVpPL52Sn-9HDCyRHnX05jIPfne4PJA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nb9QwELWqIiQuiG_ClwzihJSSxHacHBBaCtUWdotEu1Jvlu3Y25Qk2-4miOXXM3ayFQu9cInkOHIkv7HnPXk8g9BrRVWsLWUhIXER0tioMNe5CYlRSkl4EO4uCk-P0vGMfj5lpztoU95qmMDVtdLO1ZOaLau9n5fr97Dg3znFCf72rS3rugOpl8R7YK85BwV_IwHH6CK8pgPbP-_JMCG-5GacpjQEU6b9Oef1o2x5Kp_QH_zPmQuX_JeL_h1S-YePOriDbg_kEo96a7iLdkxzD93sy02u76NfQyZcfDgJY4aP27Ieindh2RT4EHYG2AALXJ98_YaPy7nj6M3c901NC9ZSlasalw0-kj5bB_7iLxLifVNVK_zRX3jEI921Bk_XplqUBZ6Y7rupS_kAzQ4-neyPw6H2QqhBA7Wh5rKglme5odxIEiXGZtbC-idpJBkBYlAwlWc0sdTmOi6ApgGTUVrnoICUZeQh2m0WjXmMcAGMJDIkY5GNqOJUaqW5ldoyBXCkJEBvNvMsLvoUGwKkiQNFeFCEA0X0oATog0Pi6kOXHdu_WCznYlhsgvI0tybNFHM3hQuwOmgSzo12pslkgF4BjltjjEcT4d5FBPgt0OAfcYBebmAWsOTcOYpszKJbCRCdqUuilSUBetTDfjUWoTkoMMICxLcMYutn2z1NeebTeoN0ddkPn_zPdDxFt1zLxdfE_BnabZedeQ4sqVUvvO3_Bu3VD9M priority: 102 providerName: Scholars Portal |
Title | Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34975835 https://search.proquest.com/docview/2616281882 https://amu.hal.science/hal-03566016 https://pubmed.ncbi.nlm.nih.gov/PMC8718679 https://doaj.org/article/4769fe68b51142dbbb9fe377ecb4b15a |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa2SUi8IBi3cJkM4gkpbVLbcfJYykYHzUBsk_oW2Y7dZSTptCZI49dz7CRjhTdeLOUe5fuc853kXBB6J6kMlaHMJyTMfRpq6Scq0T7RUkoBA-E2UTg9iebn9POSLXcQG3JhXNC-ksWoLqtRXVy42MqrSo2HOLHxt3QGIt_WiRvvol0wv3dc9MtO8hJCWPcHExywZGyKqmrBFZyEI-Bzwm33N0ITUMquydsfc-Sq9oORubAxkf8Kzr_jJu8YoqOH6EGvIPG0u9NHaEfX--he11Py5jH61Ze7xccLP2T4tCmqvkMXFnWOj2H6w1sux9XZ1-_4tFhZIV6v3LZUN0CJsthUuKjxiXAlOfAXly2IZ7osN_ijy2rEU9U2Gqc3ulwXOV7o9oeuCvEEnR8dns3mft9gwVfg6DS-4iKnhseJplwLEky0iY2BSU6iQDAC1j9nMonpxFCTqDAHLQZyRSqVgJsjDSNP0V69rvVzhHOQHYEmMQtMQCWnQknFjVCGSUAjIh56Pzzn7Kqro5GB_2HxyRw-mcUn6_Dx0AeLxO2OtgS2W7G-XmU9ETLKo8ToKJbMpgPnQC1YJJxrZfnHhIfeAo5b55hPF5ldFxAQsaB1f4YeejPAnMG8sj9LRK3X7SYDzzKylbLiiYeedbDfnmsgj4f4FiG2Lra9Bajsanf31H3x30e-RPftk7IRNSF_hfaa61a_Bl3UyAP3PQHGT8sQxpTGB25m_AasJxGm |
link.rule.ids | 230,314,727,780,784,864,885,2102,24318,27924,27925,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLXGEIIXxJ1wNYgnpKxJbcfxYylMLWsLYp20N8t27C7QpNOaIo1fz2cnHSu88RIpdm7yOY7PJ38XhN5pqlPjKIsJSYuYplbHwggbE6u1VnAg3AcKT2fZ6IR-PmWne4htY2GC077R5UG9rA7q8iz4Vp5Xprf1E-t9nQ5B5Ps8cb0b6CYjXKTXjPTvreglhLB2DxNMMNFzZVVtwBjspwfAaMF9_TdCBWjlUObtz4IU8vbDMnPmvSL_lZx_e05eW4oO76G7nYbEg_Zb76M9Wz9At9qqkpcP0a8u4S0eT-KU4eOmrLoaXVjVBR7DDwD-cwWu5l--4eNy4aV4vQh9U9sAKZblusJljWcqJOXARyFeEA_tcrnGH0NcIx6YTWPx9NIuV2WBJ3bzw1aleoRODj_Nh6O4K7EQGzB1mthwVVDHc2Ept4okfety52CakyxRjMD6XzAtctp31AmTFqDGQLBoYwQYOtox8hjt16vaPkW4AOGRWJKzxCVUc6qMNtwp45gGNDISoffbcZbnbSYNCRaIx0cGfKTHR7b4ROiDR-LqQp8EOzSsLhayo4KkPBPOZrlmPiC4AHLBKeHcGs9ApiL0FnDcecZoMJG-LSEgY0Ht_kwj9GYLs4SZ5bdLVG1Xm7UE2zLzubLyfoSetLBfPWtLngjxHULsvGy3B8gcsnd35H3233e-RrdH8-lETsazo-fojh8171-T8hdov7nY2Jegkhr9KsyJ3-p1Ejs |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgCMQL4nOET4N4Qkqb1HacPJaOqmVtmdgm7c2yHbsLNGm1pkjj13PtpKOFN14ixU6cyOfYPle-vhehD4qqWFvKQkLiPKSxUWGmMxMSo5SScCHcHRSezpLROf1ywS52Un15p32tik61KDtVcel9K1el7m79xLon0wGIfBcnrrvKbfc2usMIkGzHUP_eCF9CCGv2McEMy7q2KMsNGIS9uAOszrjLAUdoBnrZp3r7syj52P2w1Fw6z8h_Zeff3pM7y9HwIXrQ6kjcb_73EbplqsfobpNZ8voJ-tUGvcXjSRgzfFoXZZunC8sqx2OYBGCuy3F59vUbPi3mTo5Xc183NTUQY1GsS1xUeCZ9YA587M8M4oFZLNb4yJ9txH29qQ2eXpvFssjxxGx-mLKQT9H58PPZYBS2aRZCDeZOHWouc2p5mhnKjSRRz9jUWhjqJIkkI6ABcqaylPYstZmOc1BkIFqU1hkYO8oy8gwdVMvKPEc4B_ERGZKyyEZUcSq10txKbZkCNBISoI_bfharJpqGACvE4SM8PsLhIxp8AvTJIXHzoAuE7QuWV3PR0kFQnmTWJKli7lBwDgSDW8K50Y6FTAboPeC418aoPxGuLCIgZUHx_owD9G4Ls4DR5bZMZGWWm7UA-zJx8bLSXoAOG9hv2tqSJ0B8jxB7H9uvAUL7CN4tgV_895tv0b2To6GYjGfHL9F912nOxSbmr9BBfbUxr0Eo1eqNHxK_AdNFE04 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chronic+IL-15+Stimulation+and+Impaired+mTOR+Signaling+and+Metabolism+in+Natural+Killer+Cells+During+Acute+Myeloid+Leukemia&rft.jtitle=Frontiers+in+immunology&rft.au=Bou-Tayeh%2C+Berna&rft.au=Laletin%2C+Vladimir&rft.au=Salem%2C+Nassim&rft.au=Just-Landi%2C+Sylvaine&rft.date=2021-12-17&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=12&rft_id=info:doi/10.3389%2Ffimmu.2021.730970&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2021_730970 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |